GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6572 GR 55562 dihydrochlorideSummary: 5-HT1B (5-HT1Dβ) silent antagonist -
B6573 WIN 64338 hydrochlorideSummary: bradykinin B2 receptor antagonist, competitive -
B6574 BW 723C86 hydrochlorideTarget: 5-HT2 ReceptorsSummary: 5-HT2B agonist -
B6587 (+)-SK&F 10047 hydrochlorideSummary: prototypical σ1 receptor agonist -
B6596 Procaterol hydrochlorideSummary: β2 agonist -
B6597 2-Cl-IB-MECASummary: A3 adenosine receptor agonist -
B6601 ACPT-IISummary: metabotropic receptor antagonist -
B6607 (S)-(+)-Niguldipine hydrochlorideSummary: L-type Ca2+ channel blocker and α1A-adrenoceptor antagonist -
B6610 BRL 44408 (maleate)Summary: Selective α2A-AR antagonist -
B6611 CGP 12177 hydrochlorideSummary: β1/β2-AR antagonist,β3 AR partial agonist

